(2015), The human meniscus: A review of anatomy, function, injury, and advances in treatment
Subcutaneous liraglutide 3 mg (once daily) and semaglutide 2.4 mg (once weekly) have been approved for obesity management and a higher dose of subcutaneous semaglutide (7.2 mg once weekly) is currently assessed in a phase 3 trial (Table 1)
Additionally, it can provide an energy boost and reduce fatigue, which can be beneficial during a weight loss journey
Documented mechanisms of action Preclinical studies (mostly Russian, to be reproduced in international protocols) report several mechanistic targets: BDNF increase (Brain-Derived Neurotrophic Factor) in the hippocampus and frontal cortex, measured by ELISA and Western blot 24-72 h post-administration Monoaminergic system modulation : cortical dopamine increase, serotonergic modulation Activation of the melanocortin pathway via MC4R receptors (residue shared with ACTH) Anti-oxidant and anti-apoptotic effect in cerebral ischaemia models (MCAO, middle cerebral artery occlusion) Experimental paradigms The most reported rodent models are the Morris water maze (spatial memory), novel object recognition (recognition memory), passive avoidance (aversive learning)

Unlike many peptides that are unstable in physiological conditions, BPC-157 has demonstrated remarkable stability in both acidic (gastric) and neutral (plasma) environments in published research a property that has made it one of the most studied peptides for tissue repair across more than 100 independent pre-clinical investigations